Leidos said fiscal 2024 revenue for Q1 (quarter ended March 29, 2024) rose to $3,975 million, up from $3,699 million a year earlier and 7% higher, and net income was $283 million, or $2.07 per diluted share.

1. 01

   Leidos said fiscal 2024 revenue for Q1 (quarter ended March 29, 2024) rose to $3,975 million, up from $3,699 million a year earlier and 7% higher, and net income was $283 million, or $2.07 per diluted share.

2. 02

   The company said adjusted EBITDA for Q1 was $490 million ($346 million a year earlier), and adjusted EBITDA margin was 12.3% (9.4% a year earlier). The company cited higher volumes on fixed-rate managed health services and improved cost control across the company as factors behind the profit increase.

3. 03

   The company said it generated $63 million of net cash from operating activities and $46 million of free cash flow (non-GAAP) in Q1. It returned $236 million to shareholders in the same quarter, consisting of $183 million in share repurchases and $53 million in dividends.

4. 04

   The company said it changed its full-year 2024 revenue outlook to $16.0 billion to $16.4 billion from $15.7 billion to $16.1 billion, and its non-GAAP diluted EPS outlook to $8.40 to $8.80 from $7.50 to $7.90.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.